European Medicines Agency is attacked over proposal to allow technology assessment bodies to sell advice to drug industryBMJ 2014; 349 doi: https://doi.org/10.1136/bmj.g4674 (Published 17 July 2014) Cite this as: BMJ 2014;349:g4674
- Jacqui Wise
The European Medicines Agency has been criticised over its plan to allow health technology assessment bodies to provide confidential advice to drug companies in exchange for fees. A coalition of medicine advocates denounced the practice, which they said was a clear conflict of interest.
The agency has provided scientific advice to the drug industry for a fee since 2005. A “basic fee” in 2014 for an initial request for scientific advice on safety and clinical development is €83 600 (£66 000; $113 170). In 2010 a pilot project started that allowed health technology assessment bodies to also give advice to drug companies when they were at an early stage of developing a drug. And in May this year the agency released for public consultation draft guidance to extend this parallel scientific advice.1 The consultation process ended on 14 July.
Health Action International Europe, the International Society of Drug Bulletins, the Medicines in Europe Forum, and the …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial